echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Accelerate the development of mRNA vaccines Sanofi plans to develop 6 clinical-phase candidate products within 4 years

    Accelerate the development of mRNA vaccines Sanofi plans to develop 6 clinical-phase candidate products within 4 years

    • Last Update: 2021-08-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 29, 2021, Sanofi announced that it will invest approximately 400 million euros a year to establish the first mRNA vaccine center of excellence (Center of Excellence)


    The Center of Excellence will advance the cooperation agreement reached by Sanofi Pasteur and Translate Bio, the vaccine division of Sanofi, in 2018 and expanded in 2020 to develop innovative mRNA vaccine portfolios


    Note: The original text has been deleted

    Reference materials:

    [1] Sanofi launches dedicated vaccines mRNA Center of Excellence.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.